Identification of hypermethylated genes in nasopharyngeal carcinoma cell line by proteomics

Progress in Biochemistry and Biophysics

Volumn 35, Issue 4, 2008, Pages 410-417

  Zhang, Wen Jing ^a   Yi, Bin ^a   Yi, Hong ^a   Zhang, Peng Fei ^a   Li, Mao Yu ^a   Li, Cui ^a   Ruan, Lin ^a   Chen, Zhu Chu ^a   Li, Jian Ling ^a   Xiao, Zhi Qiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Methylation silenced genes; Methylation specific PCR; Nasopharyngeal carcinoma; Nm23 H1; Proteomics

Indexed keywords

EID: 48449099566     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jones P A, Laird P W. Cancer epigenetics comes of age. Nat Genet, 1999, 21(2): 163-167
2. Jones P A. Epigenetics in carcinogenesis and cancer prevention. Ann N Y Acad Sci, 2003, 983: 213-219
3. Herman J G, Baylin S B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 2003, 349(21): 2042-2054
4. Costello J F, Fruhwald M C, Smiraglia D J, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet, 2000, 24(2): 132-138
5. Baylin S B, Herman J G, Graff J R, et al. Alternations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res, 1988, 72: 141-196
6. Merlo A, Herman J G, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med, 1995, 1(7): 686-692
7. Hsu H S, Wen C K, Tang Y A, et al. Promoter hypennethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res, 2005, 11(15): 5410-5416
8. Schildhaus H U, Krockel I, Lippert H, et al. Promoter hypennethylation of p16INK4a, E-cadherin, 06-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol, 2005, 26(6): 1493-1500
9. Fraga M F, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques, 2002, 33(3): 632, 634, 636-649
10. Kwong J, Lo K W, To K F, et al. Promoter hypennethylation of multiple gene in nasopharyngeal carcinoma. Clin Cancer Res, 2002, 8(1): 131-137
11. Lo K W, Kwong J, Hui A B, et al. High frequency of promoter hypennethylation of RASSFIA in nasopharyngeal carcinoma. Cancer Res, 2001, 61(10): 3877-3881
12. Zhou L, Jiang W, Ren C, et al. Frequent hypennethylation of RASSFIA and TSLC1, and high viral load of Epstein-Ban virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia, 2005, 7(9): 809-815
13. Chinese source
14. SONG L B, YAN J, JIAN S W, et al. Chinese Journal of Cancer, 2002, 21(2): 158-162
15. Chinese source
16. FENG X P, CHEN Z C, XIAO Z Q, et al. Prog Biochem Biophys, 2005, 32(4): 338-346
17. Lo K W, Huang D P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol, 2002, 12(6): 451-462
18. Steeg P S, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst, 1988, 80(3): 200-204
19. Freije J M, MacDonald N J, Steeg P S, et al. Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symp, 1998, 63: 261-271